106827-26-3

Usage

Uses

Used in Pharmaceutical Industry:
5-(2,3-Dichlorophenyl)-2-furaldehyde is used as an intermediate in the synthesis of pharmaceuticals for its potent inhibitory effect on the enzyme poly(ADP-ribose) polymerase (PARP). This enzyme plays a crucial role in DNA repair, and by inhibiting PARP, DCPF has been studied for its potential use in cancer treatment, particularly in combination with other therapies to enhance their efficacy.
Used in Agrochemical Industry:
In the agrochemical industry, 5-(2,3-Dichlorophenyl)-2-furaldehyde serves as an intermediate in the synthesis of various agrochemicals. Its unique chemical properties make it a valuable component in the development of new pesticides and other agricultural chemicals to improve crop protection and yield.
Used in Environmental Research:
5-(2,3-Dichlorophenyl)-2-furaldehyde has been identified as a potential environmental pollutant, and its impact on human health and the environment is a subject of ongoing research. As a result, DCPF is used in environmental studies to assess its presence, distribution, and potential effects on ecosystems and human populations.

InChI:InChI=1/C11H6Cl2O2/c12-9-3-1-2-8(11(9)13)10-5-4-7(6-14)15-10/h1-6H

Upstream product

• 1899-24-7 5-bromo-2-furancarboxaldehyde 

Relevant academic research and scientific papers

Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations

Protein arginine methyltransferase 5 (PRMT5) is an important protein arginine methyltransferase that catalyzes the symmetric dimethylation of arginine resides on histones or non-histone substrate proteins. It has been thought as a promising target for many diseases, particularly cancer. Despite the potential applications of PRMT5 inhibitors in cancer treatment, very few of PRMT5i have been publicly reported. In this investigation, virtual screening and structure–activity relationship studies were carried out to discover novel PRMT5i, which finally led to the identification of a number of new PRMT5i. The most active compound, P5i-6, exhibited a considerable inhibitory potency against PRMT5 with an IC50 value of 0.57?μm, and a high selectivity for PRMT5 against other tested PRMTs. It displayed a very good antiviability activity against two colorectal cancer cell lines, HT-29 and DLD-1, and one hepatic cancer cell line, HepG2, in a sensitivity assay against 36 different cancer cell lines. Western blot assays indicated that P5i-6 selectively inhibited the symmetric dimethylations of H4R3 and H3R8 in DLD-1 cells. Overall, P5i-6 could be used as a chemical probe to investigate new functions of PRMT5 in biology and also served as a good lead compound for the development of new PRMT5-targeting therapeutic agents.